Related references
Note: Only part of the references are listed.Pharmacokinetics
Jianghong Fan et al.
BIOCHEMICAL PHARMACOLOGY (2014)
The Genomic Storm Induced by Bacterial Endotoxin Is Calmed by a Nuclear Transport Modifier That Attenuates Localized and Systemic Inflammation
Antonio DiGiandomenico et al.
PLOS ONE (2014)
A Sceptics View: Kleiber's Law or the 3/4 Rule is neither a Law nor a Rule but Rather an Empirical Approximation
A. J. Hulbert
SYSTEMS (2014)
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Models of Physiology and Physiologically Based Models in Clinical Pharmacology
A. J. Atkinson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
The determination and interpretation of the therapeutic index in drug development
Patrick Y. Muller et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Of Mice and Men: Divergence of Gene Expression Patterns in Kidney
Lydie Cheval et al.
PLOS ONE (2012)
Population Pharmacokinetic Modeling of trans-Resveratrol and Its Glucuronide and Sulfate Conjugates After Oral and Intravenous Administration in Rats
Helena Colom et al.
PHARMACEUTICAL RESEARCH (2011)
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans
John R. Cirrito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Compartmental Analysis and its Manifold Applications to Pharmacokinetics
Aldo Rescigno
AAPS JOURNAL (2010)
Of Mice and Humans: Are They the Same?-Implications in Cancer Translational Research
Marion de Jong et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Blood Collection Techniques in Exotic Small Mammals
Janis Ott Joslin
JOURNAL OF EXOTIC PET MEDICINE (2009)
Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers
Luis Almeida et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2009)
The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol
Surajit Das et al.
PHARMACEUTICAL RESEARCH (2008)
Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs
Stefan S. De Buck et al.
DRUG METABOLISM AND DISPOSITION (2007)
Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development
Iftekhar Mahmood
ADVANCED DRUG DELIVERY REVIEWS (2007)
The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials
S. Marchetti et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent
David J. Boocock et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
Chemotherapy dosing Part I: Scientific basis for current practice and use of body surface area
S. A. Kaestner et al.
CLINICAL ONCOLOGY (2007)
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α
Marie Lagouge et al.
CELL (2006)
Resveratrol improves health and survival of mice on a high-calorie diet
Joseph A. Baur et al.
NATURE (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model
Xianhua Cao et al.
PHARMACEUTICAL RESEARCH (2006)
Metabolism and bioavailability of trans-resveratrol
E Wenzel et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2005)
Allometric scaling of mammalian metabolism
CR White et al.
JOURNAL OF EXPERIMENTAL BIOLOGY (2005)
Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man
N Parrott et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Kidney mass and relative medullary thickness of rodents in relation to habitat, body size, and phylogeny
MA Al-kahtani et al.
PHYSIOLOGICAL AND BIOCHEMICAL ZOOLOGY (2004)
Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice
XF Meng et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2004)
High absorption but very low bioavailability of oral resveratrol in humans
T Walle et al.
DRUG METABOLISM AND DISPOSITION (2004)
Absorption of three wine-related polyphenols in three different matrices by healthy subjects
DA Goldberg et al.
CLINICAL BIOCHEMISTRY (2003)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
SD Baker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Inhibition of cancer growth by resveratrol is related to its low bioavailability
M Asensi et al.
FREE RADICAL BIOLOGY AND MEDICINE (2002)
Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model
JF Marier et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
How to calculate the dose of chemotherapy
H Gurney
BRITISH JOURNAL OF CANCER (2002)
Body surface area as a determinant of pharmacokinetics and drug dosing
M Sawyer et al.
INVESTIGATIONAL NEW DRUGS (2001)
Share Paper
